Novo Nordisk is continuing to lose ground in the obesity and diabetes markets, with the Danish drugmaker saying it expected sales and profit growth at the lower end of its guidance this year.

The White House is nearing an agreement with pharmaceutical companies Novo Nordisk and Eli Lilly to offer some of their weight loss drugs at a lower price through Trump Rx, a source familiar confirmed to ABC News. Under the pending agreements, a month's supply of the drugs will cost roughly $149, the source added.

Novo Nordisk said on Wednesday it has accepted the U.S. Inflation Reduction Act (IRA)'s maximum fair price for its diabetes and obesity medicines Ozempic, Wegovy and Rybelsus, which will become effective in January 2027.

Novo Nordisk (NVO) said Wednesday it has agreed to the U.S. Inflation Reduction Act’s (IRA) negotiated maximum fair prices for semaglutide, the active ingredient in its popular drugs Ozempic and Wegovy, effective January 2027. These drugs are part of the ...

Telehealth company Hims & Hers Health Inc. said late Monday it is in “active discussions” with Denmark’s Novo Nordisk A/S to make Wegovy available on its platform.

Novo Nordisk lowers its 2025 profit forecast as new CEO Mike Doustdar faces rising competition, leadership changes, and a tense takeover battle with Pfizer.

Novo Nordisk said on Wednesday it had agreed a price under the U.S. Medicare scheme for semaglutide, the active ingredient in its key drugs Ozempic and Wegovy, in a deal that some analysts said sounded less onerous than feared.

Novo launched a rival bid to acquire American obesity biotech firm Metsera last week, superseding an offer for the firm from U.S. pharma giant Pfizer. On Monday, Pfizer said it had filed a second lawsuit against Novo and Metsera, arguing that Novo's bid for the smaller company was anticompetitive.